Danaher (NYSE:DHR) Given New $290.00 Price Target at TD Cowen

Danaher (NYSE:DHR) had its target price raised by TD Cowen from $280.00 to $290.00 in a report published on Wednesday morning, Benzinga reports. TD Cowen currently has a buy rating on the conglomerate’s stock.

DHR has been the subject of a number of other research reports. Raymond James raised their price target on Danaher from $240.00 to $270.00 and gave the company an outperform rating in a research report on Wednesday, January 31st. Robert W. Baird raised their price target on Danaher from $259.00 to $271.00 and gave the company an outperform rating in a research report on Wednesday. Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the company an equal weight rating in a research report on Wednesday. Royal Bank of Canada increased their price objective on Danaher from $254.00 to $282.00 and gave the company an outperform rating in a research note on Wednesday, January 31st. Finally, StockNews.com lowered Danaher from a buy rating to a hold rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of Moderate Buy and a consensus target price of $269.64.

Danaher Trading Up 0.3 %

NYSE:DHR opened at $246.58 on Wednesday. The stock has a fifty day moving average price of $248.87 and a two-hundred day moving average price of $231.16. The stock has a market capitalization of $182.64 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 3.79 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. Danaher has a 1 year low of $182.09 and a 1 year high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the business posted $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity

In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the transaction, the director now directly owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 106,565 shares of company stock valued at $26,641,364 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Hedge funds have recently modified their holdings of the stock. Banco Santander S.A. purchased a new stake in shares of Danaher during the 3rd quarter valued at about $683,000. First Citizens Bank & Trust Co. increased its holdings in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the period. Finally, Keybank National Association OH boosted its position in Danaher by 0.5% during the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after purchasing an additional 2,567 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.